Page 2 - Satyavrat Sath Shukla News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Published: Dec 17, 2020
CAMBRIDGE, Mass., Dec. 17, 2020 (GLOBE NEWSWIRE) Spero Therapeutics Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced the appointment of Satyavrat “Sath” Shukla, CFA, as Chief Financial Officer, effective as of January 4, 2021.
“Sath is an ideal fit for our management team given his experience leading financial strategy and executing within both clinical and commercial stage companies,” said Ankit Mahadevia, M.D., Chief Executive Officer of Spero Therapeutics. “He has extensive strategic and financial expertise, which will be instrumental in helping us to drive corporate growth through the potential commercialization of tebipenem HBr and the clinical advancement of SPR720 and SPR206. We are excited to welcome Sath to Spero and are ....

United Kingdom , Ankit Mahadevia , Stephen Dipalma , Satyavrat Sath Shukla , Yale University , Ziopharm Oncology Inc , Exchange Commission , Principal At Cornerstone Research , Harvard University , Spero Therapeutics Inc , Hayes Bartlett Inc , Compensation Committee Of Spero Board Directors , Chief Financial Officer , Chief Executive Officer , Interim Chief Financial Officer , Ziopharm Oncology , Vice President , Global Head , Corporate Finance , Vertex Pharmaceuticals , Cornerstone Research , Chartered Financial Analyst , Compensation Committee , Spero Therapeutics , Equity Incentive Plan , Nasdaq Listing Rule ,